Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis-Relapsing-Remitting”

741 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 741 results

Not applicableStudy completedNCT02403570
What this trial is testing

Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive
Turku University Hospital 21
Post-approval studies (Phase 4)Study completedNCT02499900
What this trial is testing

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Who this might be right for
Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 861
Testing effectiveness (Phase 2)Study completedNCT01006265
What this trial is testing

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Actelion 464
Not applicableActive Not RecruitingNCT06413602
What this trial is testing

The Synergistic Effects of AIH and FES in Persons With MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Shirley Ryan AbilityLab 40
Large-scale testing (Phase 3)Study completedNCT02315872
What this trial is testing

ACTH for Fatigue in Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Providence Health & Services 8
Post-approval studies (Phase 4)UnknownNCT04048577
What this trial is testing

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Berkovich, Regina MD, PhD Inc. 10
Not applicableUnknownNCT05496881
What this trial is testing

Exercise Effects in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive+2 more
University of Regina 69
Testing effectiveness (Phase 2)Ended earlyNCT01963611
What this trial is testing

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
EMD Serono 255
Large-scale testing (Phase 3)Study completedNCT00099502
What this trial is testing

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bayer 2,244
Post-approval studies (Phase 4)Study completedNCT02461069
What this trial is testing

Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital Muenster 67
Early research (Phase 1)Active Not RecruitingNCT07597668
What this trial is testing

A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations

Who this might be right for
Multiple Sclerosis
R-Pharm 180
Large-scale testing (Phase 3)Study completedNCT00213135
What this trial is testing

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
EMD Serono 1,326
Not applicableNot Yet RecruitingNCT07762040
What this trial is testing

Predictors of Progression Independent of Relapse Activity in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Assiut University 180
Large-scale testing (Phase 3)Study completedNCT00530348
What this trial is testing

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genzyme, a Sanofi Company 581
Large-scale testing (Phase 3)Looking for participantsNCT07189325
What this trial is testing

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)Anti-CD20 Therapy
University Hospital, Montpellier 250
Not applicableWithdrawnNCT04082468
What this trial is testing

VALIDATE: Factor VIII Trending for MS Relapse

Who this might be right for
Multiple Sclerosis
St. Joseph's Hospital and Medical Center, Phoenix
Large-scale testing (Phase 3)Study completedNCT02746744
What this trial is testing

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Anders Svenningsson 200
Large-scale testing (Phase 3)Study completedNCT03774407
What this trial is testing

Vaginal Estriol in Multiple Sclerosis

Who this might be right for
Multiple SclerosisNeurogenic Bladder
Texas Tech University Health Sciences Center 21
Early research (Phase 1)Study completedNCT02515695
What this trial is testing

Phase I BP Interferon (IFN) Beta-001

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Centre Hospitalier Universitaire Vaudois 12
Not applicableLooking for participantsNCT06276634
What this trial is testing

Intermittent Hypoxia in Persons With Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis-Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Shirley Ryan AbilityLab 21
Next Page